nodes	percent_of_prediction	percent_of_DWPC	metapath
Ibandronate—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000679	0.00068	CcSEcCtD
Ibandronate—Headache—Mometasone—systemic scleroderma	0.000679	0.00068	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000677	0.000678	CcSEcCtD
Ibandronate—Insomnia—Mycophenolic acid—systemic scleroderma	0.000677	0.000677	CcSEcCtD
Ibandronate—Fatigue—Leflunomide—systemic scleroderma	0.000676	0.000677	CcSEcCtD
Ibandronate—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000674	0.000675	CcSEcCtD
Ibandronate—Pruritus—Captopril—systemic scleroderma	0.000673	0.000674	CcSEcCtD
Ibandronate—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000672	0.000673	CcSEcCtD
Ibandronate—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000671	0.000672	CcSEcCtD
Ibandronate—Pain—Leflunomide—systemic scleroderma	0.000671	0.000671	CcSEcCtD
Ibandronate—Constipation—Leflunomide—systemic scleroderma	0.000671	0.000671	CcSEcCtD
Ibandronate—Infection—Lisinopril—systemic scleroderma	0.000669	0.00067	CcSEcCtD
Ibandronate—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000669	0.000669	CcSEcCtD
Ibandronate—Shock—Lisinopril—systemic scleroderma	0.000663	0.000664	CcSEcCtD
Ibandronate—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000661	0.000662	CcSEcCtD
Ibandronate—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000658	0.000659	CcSEcCtD
Ibandronate—Abdominal pain—Azathioprine—systemic scleroderma	0.000656	0.000657	CcSEcCtD
Ibandronate—Body temperature increased—Azathioprine—systemic scleroderma	0.000656	0.000657	CcSEcCtD
Ibandronate—Skin disorder—Lisinopril—systemic scleroderma	0.000654	0.000655	CcSEcCtD
Ibandronate—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000652	0.000653	CcSEcCtD
Ibandronate—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000651	0.000652	CcSEcCtD
Ibandronate—Diarrhoea—Captopril—systemic scleroderma	0.000651	0.000652	CcSEcCtD
Ibandronate—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00065	0.000651	CcSEcCtD
Ibandronate—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00065	0.000651	CcSEcCtD
Ibandronate—Feeling abnormal—Leflunomide—systemic scleroderma	0.000646	0.000647	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000646	0.000647	CcSEcCtD
Ibandronate—Fatigue—Mycophenolic acid—systemic scleroderma	0.000645	0.000646	CcSEcCtD
Ibandronate—Nausea—Mometasone—systemic scleroderma	0.000643	0.000644	CcSEcCtD
Ibandronate—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000641	0.000642	CcSEcCtD
Ibandronate—Pain—Mycophenolic acid—systemic scleroderma	0.00064	0.000641	CcSEcCtD
Ibandronate—Constipation—Mycophenolic acid—systemic scleroderma	0.00064	0.000641	CcSEcCtD
Ibandronate—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000639	0.00064	CcSEcCtD
Ibandronate—Weight decreased—Prednisone—systemic scleroderma	0.000637	0.000638	CcSEcCtD
Ibandronate—Dizziness—Captopril—systemic scleroderma	0.000629	0.00063	CcSEcCtD
Ibandronate—Depression—Prednisone—systemic scleroderma	0.000626	0.000626	CcSEcCtD
Ibandronate—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000625	0.000625	CcSEcCtD
Ibandronate—Urticaria—Leflunomide—systemic scleroderma	0.000623	0.000624	CcSEcCtD
Ibandronate—Abdominal pain—Leflunomide—systemic scleroderma	0.00062	0.000621	CcSEcCtD
Ibandronate—Body temperature increased—Leflunomide—systemic scleroderma	0.00062	0.000621	CcSEcCtD
Ibandronate—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000616	0.000617	CcSEcCtD
Ibandronate—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000616	0.000617	CcSEcCtD
Ibandronate—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000616	0.000617	CcSEcCtD
Ibandronate—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000616	0.000617	CcSEcCtD
Ibandronate—Breast disorder—Methotrexate—systemic scleroderma	0.000615	0.000616	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000614	0.000615	CcSEcCtD
Ibandronate—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000614	0.000615	CcSEcCtD
Ibandronate—Hypersensitivity—Azathioprine—systemic scleroderma	0.000612	0.000613	CcSEcCtD
Ibandronate—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000612	0.000613	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000612	0.000612	CcSEcCtD
Ibandronate—Insomnia—Lisinopril—systemic scleroderma	0.000609	0.00061	CcSEcCtD
Ibandronate—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000608	0.000609	CcSEcCtD
Ibandronate—Paraesthesia—Lisinopril—systemic scleroderma	0.000605	0.000606	CcSEcCtD
Ibandronate—Vomiting—Captopril—systemic scleroderma	0.000605	0.000606	CcSEcCtD
Ibandronate—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000602	0.000603	CcSEcCtD
Ibandronate—Rash—Captopril—systemic scleroderma	0.0006	0.000601	CcSEcCtD
Ibandronate—Dermatitis—Captopril—systemic scleroderma	0.000599	0.0006	CcSEcCtD
Ibandronate—Headache—Captopril—systemic scleroderma	0.000596	0.000597	CcSEcCtD
Ibandronate—Dyspepsia—Lisinopril—systemic scleroderma	0.000593	0.000594	CcSEcCtD
Ibandronate—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000591	0.000592	CcSEcCtD
Ibandronate—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000591	0.000592	CcSEcCtD
Ibandronate—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00059	0.000591	CcSEcCtD
Ibandronate—Asthma—Methotrexate—systemic scleroderma	0.000588	0.000589	CcSEcCtD
Ibandronate—Infection—Mycophenolate mofetil—systemic scleroderma	0.000587	0.000587	CcSEcCtD
Ibandronate—Decreased appetite—Lisinopril—systemic scleroderma	0.000586	0.000587	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000582	0.000582	CcSEcCtD
Ibandronate—Fatigue—Lisinopril—systemic scleroderma	0.000581	0.000582	CcSEcCtD
Ibandronate—Shock—Mycophenolate mofetil—systemic scleroderma	0.000581	0.000582	CcSEcCtD
Ibandronate—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000579	0.00058	CcSEcCtD
Ibandronate—Hypersensitivity—Leflunomide—systemic scleroderma	0.000578	0.000578	CcSEcCtD
Ibandronate—Constipation—Lisinopril—systemic scleroderma	0.000576	0.000577	CcSEcCtD
Ibandronate—Pain—Lisinopril—systemic scleroderma	0.000576	0.000577	CcSEcCtD
Ibandronate—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000573	0.000574	CcSEcCtD
Ibandronate—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000571	0.000571	CcSEcCtD
Ibandronate—Diarrhoea—Azathioprine—systemic scleroderma	0.000568	0.000569	CcSEcCtD
Ibandronate—Haemoglobin—Prednisone—systemic scleroderma	0.000566	0.000567	CcSEcCtD
Ibandronate—Nausea—Captopril—systemic scleroderma	0.000565	0.000566	CcSEcCtD
Ibandronate—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000564	0.000565	CcSEcCtD
Ibandronate—Haemorrhage—Prednisone—systemic scleroderma	0.000563	0.000564	CcSEcCtD
Ibandronate—Asthenia—Leflunomide—systemic scleroderma	0.000563	0.000563	CcSEcCtD
Ibandronate—Feeling abnormal—Lisinopril—systemic scleroderma	0.000555	0.000556	CcSEcCtD
Ibandronate—Pruritus—Leflunomide—systemic scleroderma	0.000555	0.000556	CcSEcCtD
Ibandronate—Connective tissue disorder—Prednisone—systemic scleroderma	0.000554	0.000554	CcSEcCtD
Ibandronate—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000551	0.000552	CcSEcCtD
Ibandronate—Dizziness—Azathioprine—systemic scleroderma	0.000549	0.00055	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000547	0.000547	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000538	0.000539	CcSEcCtD
Ibandronate—Asthenia—Mycophenolic acid—systemic scleroderma	0.000537	0.000537	CcSEcCtD
Ibandronate—Diarrhoea—Leflunomide—systemic scleroderma	0.000537	0.000537	CcSEcCtD
Ibandronate—Urticaria—Lisinopril—systemic scleroderma	0.000535	0.000536	CcSEcCtD
Ibandronate—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000534	0.000535	CcSEcCtD
Ibandronate—Body temperature increased—Lisinopril—systemic scleroderma	0.000533	0.000533	CcSEcCtD
Ibandronate—Abdominal pain—Lisinopril—systemic scleroderma	0.000533	0.000533	CcSEcCtD
Ibandronate—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00053	0.000531	CcSEcCtD
Ibandronate—Pruritus—Mycophenolic acid—systemic scleroderma	0.000529	0.00053	CcSEcCtD
Ibandronate—Vomiting—Azathioprine—systemic scleroderma	0.000528	0.000529	CcSEcCtD
Ibandronate—Pneumonia—Methotrexate—systemic scleroderma	0.000527	0.000528	CcSEcCtD
Ibandronate—Eye disorder—Prednisone—systemic scleroderma	0.000526	0.000527	CcSEcCtD
Ibandronate—Infestation NOS—Methotrexate—systemic scleroderma	0.000524	0.000525	CcSEcCtD
Ibandronate—Infestation—Methotrexate—systemic scleroderma	0.000524	0.000525	CcSEcCtD
Ibandronate—Rash—Azathioprine—systemic scleroderma	0.000524	0.000524	CcSEcCtD
Ibandronate—Dermatitis—Azathioprine—systemic scleroderma	0.000523	0.000524	CcSEcCtD
Ibandronate—Depression—Methotrexate—systemic scleroderma	0.000523	0.000524	CcSEcCtD
Ibandronate—Headache—Azathioprine—systemic scleroderma	0.00052	0.000521	CcSEcCtD
Ibandronate—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00052	0.00052	CcSEcCtD
Ibandronate—Dizziness—Leflunomide—systemic scleroderma	0.000519	0.000519	CcSEcCtD
Ibandronate—Renal failure—Methotrexate—systemic scleroderma	0.000515	0.000516	CcSEcCtD
Ibandronate—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000513	0.000514	CcSEcCtD
Ibandronate—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000512	0.000513	CcSEcCtD
Ibandronate—Stomatitis—Methotrexate—systemic scleroderma	0.000511	0.000512	CcSEcCtD
Ibandronate—Angiopathy—Prednisone—systemic scleroderma	0.000511	0.000512	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00051	0.00051	CcSEcCtD
Ibandronate—Immune system disorder—Prednisone—systemic scleroderma	0.000509	0.000509	CcSEcCtD
Ibandronate—Pain—Mycophenolate mofetil—systemic scleroderma	0.000505	0.000506	CcSEcCtD
Ibandronate—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000505	0.000506	CcSEcCtD
Ibandronate—Sweating—Methotrexate—systemic scleroderma	0.000503	0.000503	CcSEcCtD
Ibandronate—Vomiting—Leflunomide—systemic scleroderma	0.000499	0.000499	CcSEcCtD
Ibandronate—Alopecia—Prednisone—systemic scleroderma	0.000498	0.000498	CcSEcCtD
Ibandronate—Hypersensitivity—Lisinopril—systemic scleroderma	0.000496	0.000497	CcSEcCtD
Ibandronate—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000496	0.000497	CcSEcCtD
Ibandronate—Dizziness—Mycophenolic acid—systemic scleroderma	0.000495	0.000495	CcSEcCtD
Ibandronate—Rash—Leflunomide—systemic scleroderma	0.000494	0.000495	CcSEcCtD
Ibandronate—Dermatitis—Leflunomide—systemic scleroderma	0.000494	0.000495	CcSEcCtD
Ibandronate—Mental disorder—Prednisone—systemic scleroderma	0.000493	0.000494	CcSEcCtD
Ibandronate—Nausea—Azathioprine—systemic scleroderma	0.000493	0.000494	CcSEcCtD
Ibandronate—Headache—Leflunomide—systemic scleroderma	0.000491	0.000492	CcSEcCtD
Ibandronate—Malnutrition—Prednisone—systemic scleroderma	0.00049	0.000491	CcSEcCtD
Ibandronate—Erythema—Prednisone—systemic scleroderma	0.00049	0.000491	CcSEcCtD
Ibandronate—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000486	0.000487	CcSEcCtD
Ibandronate—Asthenia—Lisinopril—systemic scleroderma	0.000483	0.000484	CcSEcCtD
Ibandronate—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000483	0.000483	CcSEcCtD
Ibandronate—Pruritus—Lisinopril—systemic scleroderma	0.000477	0.000477	CcSEcCtD
Ibandronate—Vomiting—Mycophenolic acid—systemic scleroderma	0.000476	0.000476	CcSEcCtD
Ibandronate—Haemoglobin—Methotrexate—systemic scleroderma	0.000473	0.000474	CcSEcCtD
Ibandronate—Rash—Mycophenolic acid—systemic scleroderma	0.000472	0.000472	CcSEcCtD
Ibandronate—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000471	0.000472	CcSEcCtD
Ibandronate—Haemorrhage—Methotrexate—systemic scleroderma	0.000471	0.000471	CcSEcCtD
Ibandronate—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000469	0.00047	CcSEcCtD
Ibandronate—Headache—Mycophenolic acid—systemic scleroderma	0.000469	0.000469	CcSEcCtD
Ibandronate—Pharyngitis—Methotrexate—systemic scleroderma	0.000467	0.000468	CcSEcCtD
Ibandronate—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000467	0.000467	CcSEcCtD
Ibandronate—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000467	0.000467	CcSEcCtD
Ibandronate—Nausea—Leflunomide—systemic scleroderma	0.000466	0.000466	CcSEcCtD
Ibandronate—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000465	0.000465	CcSEcCtD
Ibandronate—Urethral disorder—Methotrexate—systemic scleroderma	0.000461	0.000462	CcSEcCtD
Ibandronate—Diarrhoea—Lisinopril—systemic scleroderma	0.000461	0.000462	CcSEcCtD
Ibandronate—Ill-defined disorder—Prednisone—systemic scleroderma	0.000455	0.000456	CcSEcCtD
Ibandronate—Anaemia—Prednisone—systemic scleroderma	0.000453	0.000454	CcSEcCtD
Ibandronate—Angioedema—Prednisone—systemic scleroderma	0.000448	0.000449	CcSEcCtD
Ibandronate—Dizziness—Lisinopril—systemic scleroderma	0.000446	0.000446	CcSEcCtD
Ibandronate—Nausea—Mycophenolic acid—systemic scleroderma	0.000444	0.000445	CcSEcCtD
Ibandronate—Malaise—Prednisone—systemic scleroderma	0.000442	0.000443	CcSEcCtD
Ibandronate—Vertigo—Prednisone—systemic scleroderma	0.000441	0.000441	CcSEcCtD
Ibandronate—Eye disorder—Methotrexate—systemic scleroderma	0.00044	0.000441	CcSEcCtD
Ibandronate—Cardiac disorder—Methotrexate—systemic scleroderma	0.000437	0.000437	CcSEcCtD
Ibandronate—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000435	0.000436	CcSEcCtD
Ibandronate—Vomiting—Lisinopril—systemic scleroderma	0.000428	0.000429	CcSEcCtD
Ibandronate—Angiopathy—Methotrexate—systemic scleroderma	0.000427	0.000428	CcSEcCtD
Ibandronate—Immune system disorder—Methotrexate—systemic scleroderma	0.000425	0.000426	CcSEcCtD
Ibandronate—Rash—Lisinopril—systemic scleroderma	0.000425	0.000425	CcSEcCtD
Ibandronate—Dermatitis—Lisinopril—systemic scleroderma	0.000424	0.000425	CcSEcCtD
Ibandronate—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000424	0.000425	CcSEcCtD
Ibandronate—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000424	0.000424	CcSEcCtD
Ibandronate—Hypertension—Prednisone—systemic scleroderma	0.000423	0.000424	CcSEcCtD
Ibandronate—Chills—Methotrexate—systemic scleroderma	0.000422	0.000423	CcSEcCtD
Ibandronate—Headache—Lisinopril—systemic scleroderma	0.000422	0.000423	CcSEcCtD
Ibandronate—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000418	0.000418	CcSEcCtD
Ibandronate—Arthralgia—Prednisone—systemic scleroderma	0.000417	0.000418	CcSEcCtD
Ibandronate—Myalgia—Prednisone—systemic scleroderma	0.000417	0.000418	CcSEcCtD
Ibandronate—Anxiety—Prednisone—systemic scleroderma	0.000416	0.000417	CcSEcCtD
Ibandronate—Alopecia—Methotrexate—systemic scleroderma	0.000416	0.000417	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000415	0.000415	CcSEcCtD
Ibandronate—Discomfort—Prednisone—systemic scleroderma	0.000412	0.000413	CcSEcCtD
Ibandronate—Mental disorder—Methotrexate—systemic scleroderma	0.000412	0.000413	CcSEcCtD
Ibandronate—Malnutrition—Methotrexate—systemic scleroderma	0.00041	0.00041	CcSEcCtD
Ibandronate—Erythema—Methotrexate—systemic scleroderma	0.00041	0.00041	CcSEcCtD
Ibandronate—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000404	0.000404	CcSEcCtD
Ibandronate—Dysgeusia—Methotrexate—systemic scleroderma	0.000401	0.000402	CcSEcCtD
Ibandronate—Nausea—Lisinopril—systemic scleroderma	0.0004	0.000401	CcSEcCtD
Ibandronate—Anaphylactic shock—Prednisone—systemic scleroderma	0.0004	0.000401	CcSEcCtD
Ibandronate—Infection—Prednisone—systemic scleroderma	0.000398	0.000398	CcSEcCtD
Ibandronate—Back pain—Methotrexate—systemic scleroderma	0.000396	0.000397	CcSEcCtD
Ibandronate—Shock—Prednisone—systemic scleroderma	0.000394	0.000394	CcSEcCtD
Ibandronate—Nervous system disorder—Prednisone—systemic scleroderma	0.000392	0.000393	CcSEcCtD
Ibandronate—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00039	0.000391	CcSEcCtD
Ibandronate—Skin disorder—Prednisone—systemic scleroderma	0.000389	0.000389	CcSEcCtD
Ibandronate—Hyperhidrosis—Prednisone—systemic scleroderma	0.000387	0.000387	CcSEcCtD
Ibandronate—Ill-defined disorder—Methotrexate—systemic scleroderma	0.00038	0.000381	CcSEcCtD
Ibandronate—Anaemia—Methotrexate—systemic scleroderma	0.000379	0.000379	CcSEcCtD
Ibandronate—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000375	0.000376	CcSEcCtD
Ibandronate—Rash—Mycophenolate mofetil—systemic scleroderma	0.000372	0.000373	CcSEcCtD
Ibandronate—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000372	0.000372	CcSEcCtD
Ibandronate—Headache—Mycophenolate mofetil—systemic scleroderma	0.00037	0.00037	CcSEcCtD
Ibandronate—Malaise—Methotrexate—systemic scleroderma	0.00037	0.00037	CcSEcCtD
Ibandronate—Vertigo—Methotrexate—systemic scleroderma	0.000368	0.000369	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000365	0.000365	CcSEcCtD
Ibandronate—Insomnia—Prednisone—systemic scleroderma	0.000362	0.000362	CcSEcCtD
Ibandronate—Paraesthesia—Prednisone—systemic scleroderma	0.000359	0.00036	CcSEcCtD
Ibandronate—Dyspepsia—Prednisone—systemic scleroderma	0.000352	0.000353	CcSEcCtD
Ibandronate—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000351	0.000351	CcSEcCtD
Ibandronate—Arthralgia—Methotrexate—systemic scleroderma	0.000349	0.000349	CcSEcCtD
Ibandronate—Chest pain—Methotrexate—systemic scleroderma	0.000349	0.000349	CcSEcCtD
Ibandronate—Myalgia—Methotrexate—systemic scleroderma	0.000349	0.000349	CcSEcCtD
Ibandronate—Decreased appetite—Prednisone—systemic scleroderma	0.000348	0.000348	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000346	0.000347	CcSEcCtD
Ibandronate—Fatigue—Prednisone—systemic scleroderma	0.000345	0.000345	CcSEcCtD
Ibandronate—Discomfort—Methotrexate—systemic scleroderma	0.000345	0.000345	CcSEcCtD
Ibandronate—Constipation—Prednisone—systemic scleroderma	0.000342	0.000343	CcSEcCtD
Ibandronate—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000334	0.000335	CcSEcCtD
Ibandronate—Infection—Methotrexate—systemic scleroderma	0.000332	0.000333	CcSEcCtD
Ibandronate—Feeling abnormal—Prednisone—systemic scleroderma	0.00033	0.00033	CcSEcCtD
Ibandronate—Nervous system disorder—Methotrexate—systemic scleroderma	0.000328	0.000328	CcSEcCtD
Ibandronate—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000327	0.000328	CcSEcCtD
Ibandronate—Skin disorder—Methotrexate—systemic scleroderma	0.000325	0.000325	CcSEcCtD
Ibandronate—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000323	0.000324	CcSEcCtD
Ibandronate—Urticaria—Prednisone—systemic scleroderma	0.000318	0.000318	CcSEcCtD
Ibandronate—Body temperature increased—Prednisone—systemic scleroderma	0.000316	0.000317	CcSEcCtD
Ibandronate—Abdominal pain—Prednisone—systemic scleroderma	0.000316	0.000317	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000305	0.000305	CcSEcCtD
Ibandronate—Insomnia—Methotrexate—systemic scleroderma	0.000302	0.000303	CcSEcCtD
Ibandronate—Paraesthesia—Methotrexate—systemic scleroderma	0.0003	0.000301	CcSEcCtD
Ibandronate—Hypersensitivity—Prednisone—systemic scleroderma	0.000295	0.000295	CcSEcCtD
Ibandronate—Dyspepsia—Methotrexate—systemic scleroderma	0.000294	0.000295	CcSEcCtD
Ibandronate—Decreased appetite—Methotrexate—systemic scleroderma	0.000291	0.000291	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000289	0.000289	CcSEcCtD
Ibandronate—Fatigue—Methotrexate—systemic scleroderma	0.000288	0.000289	CcSEcCtD
Ibandronate—Asthenia—Prednisone—systemic scleroderma	0.000287	0.000287	CcSEcCtD
Ibandronate—Pain—Methotrexate—systemic scleroderma	0.000286	0.000286	CcSEcCtD
Ibandronate—Pruritus—Prednisone—systemic scleroderma	0.000283	0.000283	CcSEcCtD
Ibandronate—Feeling abnormal—Methotrexate—systemic scleroderma	0.000276	0.000276	CcSEcCtD
Ibandronate—Diarrhoea—Prednisone—systemic scleroderma	0.000274	0.000274	CcSEcCtD
Ibandronate—FDPS—connective tissue—systemic scleroderma	0.000274	0.207	CbGeAlD
Ibandronate—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000273	0.000274	CcSEcCtD
Ibandronate—Urticaria—Methotrexate—systemic scleroderma	0.000266	0.000266	CcSEcCtD
Ibandronate—Dizziness—Prednisone—systemic scleroderma	0.000265	0.000265	CcSEcCtD
Ibandronate—Abdominal pain—Methotrexate—systemic scleroderma	0.000264	0.000265	CcSEcCtD
Ibandronate—Body temperature increased—Methotrexate—systemic scleroderma	0.000264	0.000265	CcSEcCtD
Ibandronate—Vomiting—Prednisone—systemic scleroderma	0.000254	0.000255	CcSEcCtD
Ibandronate—Rash—Prednisone—systemic scleroderma	0.000252	0.000253	CcSEcCtD
Ibandronate—Dermatitis—Prednisone—systemic scleroderma	0.000252	0.000252	CcSEcCtD
Ibandronate—Headache—Prednisone—systemic scleroderma	0.000251	0.000251	CcSEcCtD
Ibandronate—FDPS—smooth muscle tissue—systemic scleroderma	0.00025	0.189	CbGeAlD
Ibandronate—FDPS—skin of body—systemic scleroderma	0.000247	0.187	CbGeAlD
Ibandronate—Hypersensitivity—Methotrexate—systemic scleroderma	0.000246	0.000247	CcSEcCtD
Ibandronate—Asthenia—Methotrexate—systemic scleroderma	0.00024	0.00024	CcSEcCtD
Ibandronate—Nausea—Prednisone—systemic scleroderma	0.000238	0.000238	CcSEcCtD
Ibandronate—Pruritus—Methotrexate—systemic scleroderma	0.000237	0.000237	CcSEcCtD
Ibandronate—Diarrhoea—Methotrexate—systemic scleroderma	0.000229	0.000229	CcSEcCtD
Ibandronate—Dizziness—Methotrexate—systemic scleroderma	0.000221	0.000221	CcSEcCtD
Ibandronate—Vomiting—Methotrexate—systemic scleroderma	0.000213	0.000213	CcSEcCtD
Ibandronate—Rash—Methotrexate—systemic scleroderma	0.000211	0.000211	CcSEcCtD
Ibandronate—Dermatitis—Methotrexate—systemic scleroderma	0.000211	0.000211	CcSEcCtD
Ibandronate—Headache—Methotrexate—systemic scleroderma	0.00021	0.00021	CcSEcCtD
Ibandronate—Nausea—Methotrexate—systemic scleroderma	0.000199	0.000199	CcSEcCtD
Ibandronate—FDPS—digestive system—systemic scleroderma	0.000198	0.149	CbGeAlD
Ibandronate—FDPS—tendon—systemic scleroderma	0.000188	0.142	CbGeAlD
Ibandronate—FDPS—lung—systemic scleroderma	0.000165	0.125	CbGeAlD
